A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6 - Long-term Outcomes)

Trial Profile

A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN 6 - Long-term Outcomes)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms SUSTAIN-6
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 26 Jun 2018 Results of post-hoc analysis assessing whether this CV risk reduction was consistent in male and female subjects presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results from LEADER, SUSTAIN-6 and EXSCEL studies presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top